EntryPoint Capital LLC Boosts Stock Holdings in Fulgent Genetics, Inc. (NASDAQ:FLGT)

EntryPoint Capital LLC grew its holdings in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) by 85.2% during the 4th quarter, HoldingsChannel.com reports. The firm owned 20,771 shares of the company’s stock after buying an additional 9,556 shares during the period. EntryPoint Capital LLC’s holdings in Fulgent Genetics were worth $384,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the business. State Street Corp boosted its stake in shares of Fulgent Genetics by 1.4% in the third quarter. State Street Corp now owns 793,545 shares of the company’s stock valued at $17,244,000 after buying an additional 10,868 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Fulgent Genetics by 2.7% during the 3rd quarter. Geode Capital Management LLC now owns 502,869 shares of the company’s stock worth $10,930,000 after purchasing an additional 13,320 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Fulgent Genetics by 113.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 338,044 shares of the company’s stock valued at $7,346,000 after purchasing an additional 179,477 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Fulgent Genetics in the third quarter valued at about $5,854,000. Finally, Invenomic Capital Management LP boosted its holdings in Fulgent Genetics by 98.9% during the third quarter. Invenomic Capital Management LP now owns 249,747 shares of the company’s stock worth $5,427,000 after buying an additional 124,185 shares in the last quarter. 48.06% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CFO Paul Kim acquired 100,000 shares of Fulgent Genetics stock in a transaction dated Wednesday, March 5th. The shares were acquired at an average cost of $15.96 per share, for a total transaction of $1,596,000.00. Following the completion of the transaction, the chief financial officer now directly owns 348,282 shares of the company’s stock, valued at $5,558,580.72. The trade was a 40.28 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 31.76% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on FLGT. StockNews.com raised shares of Fulgent Genetics from a “sell” rating to a “hold” rating in a report on Wednesday, March 5th. Piper Sandler decreased their target price on Fulgent Genetics from $22.00 to $16.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th.

Fulgent Genetics Trading Down 0.9 %

Shares of NASDAQ FLGT opened at $16.90 on Thursday. The stock has a market cap of $521.01 million, a price-to-earnings ratio of -3.06 and a beta of 1.54. The company’s 50-day moving average price is $16.82 and its 200 day moving average price is $18.73. Fulgent Genetics, Inc. has a 52 week low of $14.57 and a 52 week high of $25.11.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.